Showing results (121-130 of 213) with videos related to

Sort By:
Pageof 22
Climacteric : the Journal of the International Menopause Society|November 22, 2021
Impact of non-hip fractures in elderly women: a narrative reviewA Charles, A Mugisha, L Iconaru, et al.
Calcified Tissue International|March 22, 2022
Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE StudyA Charles, A Mugisha, L Iconaru, et al.
JBMR Plus|December 18, 2019
Does the Prediction Accuracy of Osteoporotic Fractures by BMD and Clinical Risk Factors Vary With Fracture Site?L Iconaru, M Moreau, V Kinnard, et al.
Revue Medicale De Bruxelles|November 2, 2004
[Breast cancer treatment in 2004: towards a tailored approach]J M Nogaret, Ch Bernard-Marty, I Mancini, et al.
Cancer Treatment Reviews|November 19, 2016
Bone health in the elderly cancer patient: A SIOG position paperJ J Body, E Terpos, B Tombal, et al.
Bone Reports|May 9, 2020
What is the validity of self-reported fractures?F Baleanu, M Moreau, V Kinnard, et al.
Bone Reports|February 24, 2023
The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohortL Iconaru, A Charles, F Baleanu, et al.
Clinical Therapeutics|October 4, 2005
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United KingdomErwin De Cock, John Hutton, Peter Canney, et al.
Presse Medicale (Paris, France : 1983)|June 10, 1989
[Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients]J P Sculier, D Bron, A Delforge, et al.
British Journal of Cancer|March 18, 2004
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesJ J Body, I J Diel, M Lichinitzer, et al.
Pageof 22